Wileyfox Unveils 3 New Smartphones: Spark, Spark+ and Spark X

1

wileyfox_spark

As expected, Wileyfox has today officially unveiled its latest smartphones. The three devices, the Wileyfox Spark, Wileyfox Spark+ and Spark X will pick up from where the current Wileyfox devices, which were launched last year, the Strom and the Swift, left.

Just like the Storm and the Swift, the three smartphones will also be targeted at the budget segment of the market.

The Spark X which has a bigger battery than the Spark+, will go for £130 (about Kshs 17,600 at current exchange rates).

The Spark+ is exactly like the Spark but costs more because it has twice the storage of the latter. The Spark and Spark+ will go for £90 (Kshs 12,200) and £115 (Kshs 15,600) respectively.

All the devices run on Cyanogen OS version 13 which is based on Android 6.0 Marshmallow.

Spark Spark+ Spark X
Size & weight 143 x 70.4 x 8.65 mm, 134.5g Same as Spark 154.35 x 78.6 x 8.75mm, 162.9g
Display 5.0-inch HD, 1280 x 720 pixels, IPS LCD Same as Spark 5.5-inch HD, 1280 x 720 pixels
Processor 64-bit quad-core MediaTek MT6735A clocked at 1.3 GHz  Same as Spark 64-bit quad-core MediaTek MT6735 clocked at 1.3 GHz
Memory 8GB internal memory (expandable up to 32GB), 1GB RAM 16GB internal memory (expandable up to 32GB), 2GB RAM Same as Spark+
Camera Rear: 8MP, Front: 8MP Rear: 13MP, Front: 8MP Same as Spark+
OS CyanogenOS 13, Android 6.0 Marshmallow Same Same
Battery 2,200 mAh Same as Spark 3,000 mAh
Network 3G, LTE Same Same
Connectivity Bluetooth 4.0, Wi-Fi 802.11b/g/n Bluetooth 4.1, Wi-Fi 802.11b/g/n Same as Spark+

 

All the three devices are up for pre-order through Amazon UK and Wileyfox’s own website. Sales start from July 12th even though the Spark X is not expected in the open market until some time in August.

Previous articleLiquid Telecom Acquires South African Firm Neotel to Create Largest Pan-African Broadband Network.
Next articleGoogle+ is Celebrating its 5th Birthday Today
Emmanuel writes on mobile hardware, software and platforms.

1 COMMENT

Comments are closed.